Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

Non-small cell lung cancer (NSCLC), which represents 80–85% of lung cancer cases, is one
of the leading causes of human death worldwide. The majority of patients undergo an …

Background Oxaliplatin resistance is a major challenge for treatment of advanced colorectal
cancer (CRC). Both acquisition of epithelial-mesenchymal transition (EMT) and suppressed …

To survive, cancer cells are subjected to various internal and external adverse factors,
including genetic mutations, hypoxia, nutritional deficiencies, and drug toxicity. All of these …

Cancer ranks as the second leading cause of death worldwide, causing a large social and
economic burden. However, most anti-cancer treatments face the problems of tumor …

Cancer stem cells (CSCs) are a small subset of cells in cancers that are thought to initiate
tumorous transformation and promote metastasis, recurrence, and resistance to treatment …

Emerging evidence has reported that dysregulation of microRNAs (miRNAs) participated in
the development of diverse types of cancers. Our initial microarray‐based analysis identified …

The third most common malignancy has been identified as Colorectal cancer (CRC) that
conducive to death in most cases. Chemoresistance is a common obstacle to CRC …

Here the underlying antitumor mechanism of melatonin and its potency as a sensitizer of
paclitaxel was investigated in X02 cancer stem cells. Melatonin suppressed sphere …

Lung cancer is a complex disease associated with gene mutations, particularly mutations of
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) and epidermal growth factor receptor …